Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders Article

Kopala, L, Smith, G, Malla, A et al. (2006). Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders . Acta Psychiatrica Scandinavica, 113(SUPPL. 430), 29-39. 10.1111/j.1600-0447.2006.00759.x

cited authors

  • Kopala, L; Smith, G; Malla, A; Williams, R; Love, L; Talling, D; Balshaw, R

abstract

  • Objective: To determine how the use of the newer, so called atypical antipsychotic medications, effects the pharmacoeconomic treatment burden of schizophrenia and related conditions and to provide a clear comparison of the costs and risks associated with these atypical drugs. Method: In this 2-year, open-label, prospective study, resource utilization (RU) data were collected on 160 patients with these conditions. A comparison between risks and costs was performed by combining the generalized CNOMSS data on both economic factors and risk assessments. Results: The main findings of the study were that the total adjusted 1- and 2-year costs were lowest for quetiapine. Drug acquisition costs were lowest for risperidone for both the 1- and 2-year cohorts. Clozapine use was predictably associated with the highest overall and medication costs at both 1 and 2 years. Conclusion: Treatment with risperidone or quetiapine was associated with the lowest overall costs when compared with olanzapine or clozapine. Copyright © Blackwell Munksgaard 2006.

authors

publication date

  • January 1, 2006

published in

Digital Object Identifier (DOI)

start page

  • 29

end page

  • 39

volume

  • 113

issue

  • SUPPL. 430